AstraZeneca (AZN) Earns “Hold” Rating from Shore Capital
A number of other research firms also recently issued reports on AZN. JPMorgan Chase & Co. restated a buy rating on shares of AstraZeneca in a report on Wednesday, June 6th. Goldman Sachs Group set a GBX 3,750 ($47.84) price objective on shares of AstraZeneca and gave the stock a sell rating in a report on Wednesday, May 30th. Deutsche Bank restated a buy rating and set a GBX 6,000 ($76.54) price objective on shares of AstraZeneca in a report on Friday, July 27th. Credit Suisse Group restated an outperform rating and set a GBX 5,900 ($75.26) price objective on shares of AstraZeneca in a report on Tuesday, June 12th. Finally, Morgan Stanley set a GBX 5,250 ($66.97) target price on shares of AstraZeneca and gave the stock a neutral rating in a research note on Tuesday, May 22nd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,605.09 ($71.50).
LON AZN opened at GBX 5,930 ($75.65) on Wednesday. AstraZeneca has a 52-week low of GBX 4,260 ($54.34) and a 52-week high of GBX 5,520 ($70.42).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Google Finance
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.